Hence, our Evi1-transgenic model presents a unique opportunity to explore the role of EVI1 during the early stages of MDS, MDS/MPN, or AML diseases characterized by EVI1 overexpression. Here, RUNX1 is linked to myeloproliferative neoplasm.